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LETTERS
Scoring the Quality of Clinical Trials
To the Editor: Dr Ju¨ni and colleagues1 compared 25 check-
lists from systematic reviews. We agree that readers should be
critical of the heterogeneity of the content and results of check-
lists. Therefore, empirical studies in this field are useful. How-
ever, by using the same collection of checklists as Moher et al,2
Ju¨ni et al portray an unfair representation of the scientific de-
velopment of research groups. Our list,3 which Ju¨ni et al in-
cluded in their analysis, was developed in 1990 and published
in 1991. Thereafter, however, we have changed and hopefully
improved our checklist, according to the new insights pro-
vided by Moher et al4 and others. This has resulted in an up-
dated version of our checklist, which has been published in the
method guidelines for systematic reviews within the Co-
chrane Back Review Group.5 The updated checklist has al-
ready been used in several protocols and reviews in the mod-
ule of the Back Review Group, as well as in related journal
articles.
We agree that, based on current knowledge, the use of check-
lists is problematic. However, we argue that replications of stud-
ies like that of Ju¨ni et al should evaluate the latest versions of
checklists used by the research groups at issue, not lists from
the relatively early years of systematic review methodology. Oth-
erwise the results of such empirical studies will be of predict-
ably limited value.
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To the Editor: Dr Ju¨ni and colleagues1 illustrated the prob-
lem of rating the quality of clinical trials with summary scores
for study quality. We have 3 comments. First, in 1 of the 25
scales tested, the original authors refused to define a cut point
for quality.2 This was ignored by Ju¨ni et al, who depicted a
point the original authors merely used for illustration of a
graph as a cut point. Within the context of acupuncture in
chronic pain, this graph showed the increasing proportion of
negative study results as the quality score increased. The
graph encouraged a flexible definition of cut points.
Second, Ju¨ni et al wrote, “The importance of individual qual-
ity domains and, possibly, the direction of potential biases as-
sociated with these domains will thus vary according to the con-
text. . . .” However, in taking the 25 scales out of their highly
variable contexts and applying them to deep vein thrombosis,
they ignore their own advice.
Ju¨ni et al also claim that “[r]elevant methodological aspects
should be assessed individually and their influence on effect
sizes explored.” This leads to the conclusion that a relevant
methodological aspect could have no influence on the effect
sizes. In our opinion, such an aspect would be relevant if it is
part of an a priori idea about what constitutes scientific proof
in a given research context. When given a specific problem,
scientists draw up a methodological recipe that, if followed,
will lead to valid answers. The a priori ideas about which reci-
pes may lead to meaningful answers are grounded in theory.
However, theories themselves may be incomplete or wrong.
In this case, how can we use meta-regression to test our theo-
ries? It is similarly unclear how one should deal with design
components that are not associated with effect size. How
many meta-regressions should indicate that, for example,
intention-to-treat analysis does not influence effect sizes
before we drop this aspect from our recipe?
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To the Editor: As a coauthor of the original meta-analysis on
low-molecular-weight heparin (LMWH),1 I have often
referred to it when speaking or writing about the role of sub-
jectivity in research.2 I am therefore not entirely surprised by
the finding of Dr Ju¨ni and colleagues3 that varying judgments
on the quality of studies can lead to diametrically opposite
conclusions. Nevertheless, the solution to look at individual
elements of quality—albeit only those that are judged
important—will always remain an ad hoc decision of a meta-
analyst. Moreover, the interpretation is 1-sided: we will only
believe that quality has an influence when the higher-quality
studies find a lower effect. The undisputed advantage of indi-
vidual scoring is that one can discuss (and disagree) more
clearly whether some element of quality is important in a par-
ticular set of trials.
Ju¨ni et al conclude that different quality scores measure dif-
ferent things. Much like the decision by the individual which
quality element to scrutinize, one might tell the reader what
type of quality score one proposes. Our original quality score
was concordant with scores that predominantly reflected in-
ternal validity and study design.1,3 For medical decision mak-
ing, it is the quality of the research that counts. Other quality
scores have other uses (eg, to judge readability). Of acute in-
terest is the observation that one of the quality scores that maxi-
mally reverses our findings is a byproduct of a meta-analysis
of homeopathy with a positive outcome,2 which is scientifi-
cally impossible. Are we to infer that quality criteria that maxi-
mally suit homeopathy will also show a maximal benefit of
LMWH?
Ju¨ni et al show a strong influence of open outcome assess-
ment in heparin trials, which they judge to be important. Their
final verdict, based on their own selection of the best trials, is
in the same direction as ours: the difference between the hepa-
rins is not one of clear therapeutic superiority. The same was
concluded in a more recent meta-analysis that included more
trials4 and in other recent overviews.5 This follow-up might be
the criterion standard to decide which quality scores perform
best. In this follow-up, additional knowledge about the mecha-
nism of action of diverse heparins has also helped decide which
trial results are more credible.2,5 Rightly, Ju¨ni et al do not offer
any absolute standard to judge the quality of studies. Judg-
ment remains particular to particular trials and particular situ-
ations. In that respect, randomized trials are not different than
other study designs.
Jan P. Vandenbroucke, MD, PhD
Leiden University Medical Center
Leiden, the Netherlands
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In Reply: In our study, we repeated Nurmohamed and col-
leagues’1 meta-analysis of 17 trials of LMWH for prevention of
deep vein thrombosis, using 25 scales to identify high-quality
trials. We included all widely used scales but none produced
summary scores that were significantly associated with treat-
ment effects. Dr ter Riet and colleagues argue that our results
could be explained by the inclusion of scales that were devel-
oped for specific contexts. Dr Assendelft and colleagues imply
that our findings would have been different if we had used up-
dated versions of scales. They argue that we should have used
the 1997 version of their scale,2 which gives more weight to
the internal validity of trials, rather than the version pub-
lished in 1991.3 The revised scale is recommended by the Co-
chrane Back Review Group,2 but only 2 of the 8 reviews pub-
lished by this group in the Cochrane Library have actually used
this scale. This observation, and the large number of pub-
lished scales, underscore the uncertainty that exists in this area.
We addressed ter Riet and colleagues’ criticism by exclud-
ing the 11 scales that were only used in particular contexts.
Results were not materially altered (data available from the
authors). We examined Assendelft and colleagues’ claim by us-
ing both the old and the updated versions2,3 of their scale
(TABLE). Although classification of some trials changed, point
estimates from high-quality trials were similar to the overall
estimate, and summary scores were not significantly associ-
ated with treatment effects. This is not surprising considering
that even scales that exclusively assess items related to the in-
ternal validity of trials4 failed to detect an association with treat-
ment effects. Quality scales, including the updated version of
Assendelft and colleagues’ scale, consistently failed to show an
association with treatment effects. However, when assessing
key components of methodological quality individually, we
found that lack of blinding of outcome assessments influ-
enced effect size, with the effect of LMWH on average being
exaggerated by 35% (P,.05). Clearly, when scoring the qual-
Table. Combined Results for All 17 Trials Comparing
Low-Molecular-Weight Heparin With Standard Heparin*
No. of
Trials
Deep Vein Thrombosis
P
ValueRR (95% CI)
Ratio of RRs
(95% CI)
All trials 17 0.79 (0.65-0.95) . . . . . .
Stratified by quality†
Original scale4
High quality 12 0.74 (0.61-0.91) 1.00 (Referent)
.12
Low quality 5 1.13 (0.70-1.82) 1.53 (0.90-2.59)
Revised scale3
High quality 10 0.85 (0.68-1.08) 1.00 (Referent)
.28
Low quality 7 0.68 (0.50-0.93) 0.80 (0.54-1.19)
*Results from sensitivity analyses dividing trials in high-quality and low-quality strata, us-
ing the original and a revised version of Assendelft et al’s quality scale. RR indicates
relative risk; CI, confidence interval; and ellipses, data not available.
†Threshold for high quality set at 50% of maximum score, as proposed by the authors
of the scale.2,3
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ity of the 17 trials with scales, the points attributed to blind-
ing of outcome assessment (the factor that matters in this par-
ticular meta-analysis1) are diluted by other aspects of
methodological or reporting quality that are of limited impor-
tance in this situation. As pointed out by ter Riet and col-
leagues, not all aspects that are relevant on theoretical grounds
will matter in a given context.
We agree with Dr Vandenbroucke that scales should not be
used to identify trials of low or high quality in a given meta-
analysis. Rather, the relevant methodological aspects should
be identified a priori and checked individually. Oxman5 has
drawn an analogy with aviation to illustrate the importance of
checklists. Before takeoff, pilots use checklists to ensure that
all vital systems of the aircraft work properly. Unlike many meta-
analysts, they do not rely on scales and decide to take off if a
summary score of 50% or more is reached. Our empirical study
and theoretical considerations4 indicate that what would cer-
tainly be disastrous in aviation is also a hazardous approach
for assessing the quality of trials for systematic reviews and meta-
analyses.
Peter Ju¨ni, MD
Matthias Egger, MD, MSc
MRC HSRC, Department of Social Medicine
Bristol, England
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Sources of Bias in the Economic Analysis
of New Drugs
To the Editor: Mr Friedberg and colleagues1 found that stud-
ies sponsored by drug companies were less likely to report un-
favorable results than studies funded by nonprofit organiza-
tions. The authors posited several alternative explanations for
their findings, including publication bias, unconscious bias be-
cause of relationships between the investigator and the phar-
maceutical company, early screening of studies by drug firms,
and direct company involvement with the study design.
As noted in the accompanying editorial,2 the conflict of
interest hypothesis would be strengthened by a study design
comparing several economic evaluations, from different fund-
ing sources, of a single agent. However, the design of the study
by Friedberg et al allows alternative explanations to be consid-
ered. First, many pharmaceutical companies conduct internal
economic evaluations throughout the development of a drug
product. Because reimbursement for a drug product is often
dependent on positive economic findings,3 otherwise promis-
ing products may be terminated during development by the
drug company. Hence, drugs that are marketed are less likely
to receive an unfavorable economic evaluation, regardless of
the funding source. Second, pharmaceutical companies fund
the majority of the clinical and economic studies conducted
during drug development. Because marketed products have
demonstrated positive clinical findings during development
and because these findings often lead to positive economic
benefits, it should not be surprising that industry-sponsored
economic analyses are more frequently favorable. Third,
because drug companies are commercial enterprises, it is
appropriate for them to allocate their resources to those activi-
ties that promise the best return. It is in their interest to sub-
ject operating hypotheses to rigorous economic analyses by
funding external studies. None of these explanations are asso-
ciated with scientific bias in terms of an external researcher’s
conflict of interest.
Although it is easy to allege scientific bias arising from a con-
flict of interest,4 proving such a bias is difficult. Indeed, Fried-
berg et al acknowledged that they did not identify bias in in-
dividual studies. Rather than supporting a conflict of interest
hypothesis, this study may simply indicate that pharmaceuti-
cal firms are exhibiting rational economic behavior in their de-
velopment of new products.
Jean Paul Gagnon, PhD
for the members of the Health Outcomes Committee
Pharmaceutical Research and Manufacturers of America
Washington, DC
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To the Editor: Mr Friedberg and colleagues1 have analyzed a
sample of published pharmacoeconomic studies and found that
“pharmaceutical company-sponsored studies were less likely
than nonprofit sponsored studies to report unfavorable quali-
tative conclusions.” It is important to notice that they identi-
fied a publication bias, not a study bias. In fact they fail to find
biases in individual studies, meaning that the peer review pro-
cess work reasonably well and that individual published stud-
ies are generally reliable. However, it is also important to en-
courage publication of negative results. We recently published
a study with negative results2 despite reservations from the ref-
erees. We felt that they would have been more enthusiastic about
positive results. Clinicians may also fear that reporting nega-
tive cost-effectiveness results will reinforce nonmedical limi-
tations to their autonomy to prescribe.
It is obviously difficult to compel companies to support and
publish studies showing that their products are not cost-
effective. Because pharmacoeconomic studies are not the only
factor in medical decision making, lack of positive data is not
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necessarily an indication that the drug has no value. The so-
lution probably lies in a more systematic use of pharmacoeco-
nomic data for treatment guidelines or for decisions about re-
imbursement and pricing, in both private and public health care
settings. This would not guarantee that industry-sponsored nega-
tive results will be reported more frequently, but would allow
more appropriate interpretation of unreported results.
Claude Le Pen, PhD
University Paris-Dauphine
Paris, France
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To the Editor: Mr Friedberg and colleagues1 take a system-
atic approach to identifying the characteristics of published cost
studies. However, relying on study sponsorship as the domi-
nant criterion for evaluating potential conflict of interest may
be too simplistic. A more thorough review of methods, data
inputs, assumptions, and publication sources and their im-
pact on study conclusions is warranted. For example, prospec-
tive, randomized clinical studies (single center or multi-
center) using actual use and cost data may be less biased than
studies developed using decision analysis models. Addition-
ally, some of the studies included in the analysis were not pub-
lished in peer-reviewed journals. To combine heterogeneous
samples in drawing conclusions is improper both in clinical
research and the evaluation of conflict of interest.
Furthermore, in more than 10% of cases in which authors
were contacted regarding potential conflicts, authors and/or pub-
lishers failed to report industry relationships. Therefore, it can
be difficult for readers to fully understand potential sources of
conflict of interest unless disclosure and reporting policies are
standardized and enforced.
In evaluating the potential for biases, it may be more pru-
dent for readers to evaluate clinical and economic literature
across several criteria including sponsorship, author affilia-
tion, journal type, study methods and assumptions and the ex-
tent to which authors’ conclusions and statements are sup-
ported by the data presented. Rather than focusing solely on
pharmaceutical industry sponsorship, perhaps the best advice
should be caveat lector (let the reader beware).
Mary M. Prendergast, MBA
Fujisawa Healthcare Inc
Deerfield, Ill
1. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of con-
flict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;
282:1453-1457.
To the Editor: The article by Mr Friedberg and colleagues1 in-
cludes a statement that the sponsor had a contractual right to
review and comment on manuscripts and abstracts prior to sub-
mission. However, there is no indication of whether such
review was made, whether any comments were offered and, if
so, whether they influenced the final manuscript. Disclosure
should extend beyond the information that a review is pos-
sible and include the facts concerning the review, if one took
place, and the influence, if any, that the review had on the manu-
script. A separate question is whether investigators should sign
contracts that allow sponsors the right to review and com-
ment on data prior to peer review for publication.
Herbert Rakatansky, MD
Council on Ethical and Judicial Affairs
American Medical Association
Chicago, Ill
1. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of con-
flict of interest in economic analyses of new drugs used in oncology. JAMA. 1999;
282:1453-1457.
In Reply: We agree with Dr Gagnon that it is only rational for
pharmaceutical firms to support positive economic analyses,
although that does not preclude conflict of interest. It should
also be noted that the perspective of our study is from the sci-
entific community, not from the pharmaceutical industry. We
found that fewer studies with negative results are sponsored
by pharmaceutical firms, which leads to a bias in the available
economic literature for these drugs. As Dr Le Pen notes, phar-
macoeconomic research (and medical research in general) would
benefit from the publication of studies with both positive and
negative results.
Ms Prendergast points out that the issues of bias are com-
plex and include many factors in addition to sponsorship source,
including methods, assumptions, and publication source. We
hope that pharmaceutical companies with outcomes pro-
grams will support efforts to expand databases of cost-
effectiveness studies. This would allow for multivariate analy-
ses related to factors influencing study outcome.
In response to Dr Rakatansky’s concern, it is typical for phar-
maceutical companies to request a review period to protect the
proprietary interests of their products. In this case, the spon-
sor had 60 days to review our manuscript and offered no com-
ments or suggestions.
Mark Friedberg, BA
Northwestern University
Chicago, Ill
Bernie Saffran, PhD
Swarthmore College
Swarthmore, Pa
Tammy Stinson, MS
Charles Bennett, MD, PhD
Lakeside Veterans Affairs Medical Center
Chicago
Bisphosphonate Therapy
and Vascular Calcification
To the Editor: The 3-year, randomized controlled trial re-
ported by Dr Harris and colleagues1 demonstrated that rise-
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dronate increased bone mineral density and decreased frac-
ture incidence in postmenopausal women with established
osteoporosis. Although the overall safety profile was similar in
the placebo and risedronate groups, serious adverse events were
more common in the treatment group.
Risedronate inhibits osteoclast-mediated bone resorption.2
Vascular calcifications have similarites to bone, and macro-
phages in the vessel wall have both osteoclastic and osteoblas-
tic potential.3 It is possible that subtle changes in vascular cal-
cification occur during bisphosphonate treatment for
postmenopausal osteoporosis.4
Postmenopausal women are at higher risk for cardiovas-
cular disease.5 Changes in vascular wall calcification may
render some plaques more prone to rupture and lead to an
increased risk of cardiovascular events in this population.
Perhaps the authors can provide information on the propor-
tion of cardiovascular events in the treatment vs placebo
groups. If there was a higher cumulative incidence of cardio-
vascular events in the treatment group, this would cast
doubt on the long-term safety of bisphosphonate therapy in
postmenopausal women.
Mark R. Goldstein, MD
West Chester, Pa
1. Harris ST, Watts NB, Genant HK, et al, for the Vertebral Efficacy with Risedro-
nate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral
and nonvertebral fractures in women with postmenopausal osteoporosis: a ran-
domized controlled trial. JAMA. 1999;282:1344-1352.
2. Physicians’ Desk Reference. 53rd ed. Montvale, NJ: Medical Economics Books;
1999:2531-2533.
3. Demer LL. A skeleton in the atherosclerosis closet. Circulation. 1995;92:2029-
2032.
4. Goldstein MR. Long-term therapy for postmenopausal osteoporosis: stronger
bones but weaker arteries? Circulation. 1999;100:446-477.
5. Mosca L, Manson JE, Sutherland SE, et al. Cardiovascular disease in women: a
statement for healthcare professionals from the American Heart Association. Cir-
culation. 1997;96:2468-2482.
In Reply: Serious events reported in this study were defined
in accordance with regulatory guidelines.1 As noted in Table 3
of our article, the overall incidence of serious adverse events
reported was similar between the placebo (27%) and 5-mg rise-
dronate (29%) groups.
We performed a safety analysis focusing on major cardio-
vascular events reported during the study. Based on this analy-
sis, the most common events occurred at similar incidences be-
tween treatment groups. Cardiovascular events reported at a
cumulative incidence of more than 1% were right heart failure
(placebo, 1.6%; risedronate, 1.8%), myocardial infarction (pla-
cebo, 1.6%; risedronate, 1.5%), and cerebrovascular accident
(placebo, 1.0%; risedronate, 1.4%).
In addition, the study’s sponsor (Procter & Gamble, Cin-
cinnati, Ohio) has reviewed cardiovascular events reported in
a larger database from trials evaluating risedronate in the treat-
ment or prevention of postmenopausal and corticosteroid-
induced osteoporosis. This analysis included 4878 patients
treated with placebo and 4846 patients treated with risedro-
nate for up to 3 years. Patients also received elemental cal-
cium, 1 g/d, in most studies; cholecalciferol was provided if base-
line levels were less than the lower limit of normal. The
cumulative incidence of all cardiovascular events reported was
similar between groups, further supporting the conclusion that
risedronate treatment does not increase the occurrence of car-
diovascular events.
Dr Goldstein points to potential effects of bisphosphonates
on inhibiting macrophages in blood vessels with resulting
changes in vascular wall calcification. The concentrations of
risedronate required to directly inhibit serum macrophages are
not achieved with clinical dosages.2 While our study was not
designed to examine the effects of risedronate on vessel wall
calcification, the risedronate clinical adverse event database does
not suggest that risedronate therapy increases the risk of car-
diovascular events.
Steven T. Harris, MD
University of California, San Francisco
1. IND safety reports. In: Code of Federal Regulations: Food and Drugs. 1996:
82-84. 21 CFR §312.32.
2. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ. Heterocycle-
containing bisphosphonates cause apoptosis and inhibit bone resorption by pre-
venting protein prenylation: evidence from structure-activity relationships in J774
macrophages. J Bone Miner Res. 1998;13:1668-1678.
Vitamin D Deficiency in Women
With Hip Fracture
To the Editor: The study by Dr LeBoff and colleagues1 fur-
ther confirms the evidence that many older people have vita-
min D deficiencies and are likely to benefit by its correction.2,3
However, their data do not prove that such deficiency is the
primary, or even a major, factor in hip fractures in the elderly.
The large age difference between the hip fracture patients
and elective control patients presents problems with evalua-
tion for which statistical analysis cannot readily adjust. The
authors properly excluded patients with obvious comorbid
medical conditions, but there are important comorbidities
that are difficult to ascertain, especially in a presurgical set-
ting. Many of these can be important risk factors for falls (eg,
minor gait or balance difficulties, diminished vision, weaker
musculature, arthritic stiffness and pain, and mild dementia)
and all such conditions were surely of higher prevalence in
the (mean age) 78-year-old patients in the fracture group than
in the 64- and 70-year-old control patients. The presence of
such disabilities tends to be confirmed by the markedly
reduced patterns of prior physical activity in the fracture
patients—1.5 hours weekly vs 16 and 20 hours in control
patients. Such inactivity is in itself a potential risk factor for
falls and fractures.
One might also consider the implications of the much
lower body fat content of the fracture patients, a mean of 32%
compared with 42% and 47% in controls. The lower amounts
of body fat, as well as the lower serum albumin levels, further
suggest higher prevalence of premorbid status in these older
women, with an associated potential for falls. There have also
been some suggestions that external hip pads help to prevent
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fractures and subcutaneous hip-buttock fat “pads” appear
similarly protective.
Gerson T. Lesser, MD
The Jewish Home and Hospital
New York, NY
1. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vi-
tamin D deficiency in postmenopausal US women with acute hip fracture. JAMA.
1999;281:1505-1511.
2. Gloth FM III, Tobin JD. Vitamin D deficiency in older people. J Am Geriatr Soc.
1995;43:822-828.
3. Utiger RD. The need for more vitamin D. N Engl J Med. 1998;338:828-829.
4. Meyer HE, Tverdal A, Falch JA. BOdy height, body mass index, and fatal hip
fractures: 16 years follow-up of 674,000 Norwegian men an women. Epidemiol-
ogy. 1995;6:299-305.
In Reply: Vitamin D deficiency has been documented in older
patients in nursing homes and residential communities in the
United States, but there are few data available on vitamin D lev-
els in women with acute osteoporotic fractures. In our study we
found significant differences in vitamin D levels in the women
with hip fractures and no known secondary comorbid medical
conditions. In contrast, women admitted for elective joint re-
placement did not show vitamin D deficiency. We rigorously ex-
cluded patients with a multitude of risk factors that might pre-
dispose to osteoporosis, as indicated in Table 1 of our article.
As shown in Figure 1 of our article, we excluded 190 women
with comorbid medical conditions or those taking medications
that could affect bone. In contrast to the vitamin D deficiency
among women with hip fractures, we found that 17% of ambu-
latory women with osteoporosis by bone density criteria in an
osteoporosis program had vitamin D deficiency.1 While many
women fall without adverse skeletal effects, fractures are more
likely to occur in those who have a low bone density.
As stated by Dr Lesser, physical activity was less frequent in
the women with hip fractures. Physical inactivity is a risk factor
for osteoporosis and predisposes to reduced strength. Further-
more, the reduced physical activity may be associated with de-
creased sun exposure and reduced activation of vitamin D in the
skin. Poor health and frailty are risk factors for osteoporosis, al-
though we rigorously excluded patients who had known co-
morbid medical conditions.2 We did not evaluate gait difficul-
ties after the hip fracture. With reference to the percentage of
total body fat content in the women with hip fractures, their mean
[SD] percentage of body fat (32.1 [10.6]; Table 2) was in the
normal range (33.8 [9]) for postmenopausal women aged 70 to
79 years.3 Thus, although our study showed that women with
hip fractures had less body fat, the body fat content of the women
with hip fractures was consistent with other studies of body fat
in postmenopausal women.4 Furthermore, the mean albumin level
was in the low normal range (Table 3) as indicated in our ar-
ticle. The lower albumin levels in the women with hip fractures
may reflect poorer nutritional status in general and is a predic-
tor of vitamin D deficiency.
We concur with Lesser that external hip pads may reduce
fractures. In the population of community-dwelling women,
however, many would need to wear hip pads to reduce the in-
cidence of hip fracture. Because vitamin D deficiency is pre-
ventable and vitamin D repletion reduces the risk of hip frac-
ture, increased public awareness of good vitamin D nutrition
in postmenopausal women is of paramount importance.
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Tobacco Dependence Curricula
in Medical Schools
To the Editor: Dr Ferry and colleagues1 present results of a
national survey of the content of tobacco dependence cur-
ricula in US medical schools. Their data show that training of
US medical graduates in the treatment of tobacco dependence
is inadequate, and they report that clinical curricula involving
smoking cessation techniques with patients and evaluation of
student performance are seriously deficient.
In 1991, the Liaison Committee on Medical Education for-
mally incorporated performance-based assessment into the ac-
creditation standards of medical schools.2 We believe, based
on the overwhelming research evidence,3 that a critical part of
the medical school curriculum on smoking cessation should
be performance assessment of the clinical techniques. Key el-
ements to guide the development of performance-based as-
sessment are (1) integration of 2 or more new basic learned
capabilities, (2) observed behaviors, (3) relevant clinical tasks,
and (4) problem content at an appropriate level for medical
students.4 We feel that clinical techniques in smoking cessa-
tion fit these criteria.
The curricula on tobacco dependence and clinical treat-
ment at the Michigan State University College of Human Medi-
cine include all reported content areas1 with more than 10 hours
of required time from years 1 through 3 of medical school. The
main focus is a required assessment of smoking cessation coun-
seling techniques during the family practice clerkship in the
third year, which is standardized across 6 community sites. Stu-
dents receive 10% of their final examination grade in the clerk-
ship based on the performance assessment, and those who fail
the assessment must remediate it or fail the clerkship. Our 1998
cohort of 93 students was videotaped during a 10-minute coun-
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seling session with simulated patients. Two independent ob-
servers rated the sessions using a 10-point checklist based on
the Agency for Health Care Policy and Research (now called
the Agency for Healthcare Research and Quality [AHRQ]) cri-
teria. Student scores ranged from 6.5 to 10. Only 10% of the
scores were below 8, with a high level of interobserver agree-
ment (r = 0.847).
Our data show that students can readily learn cessation coun-
seling skills and such performance can be reliably evaluated.
William Wadland, MD, MS
Carole Keefe, PhD
Margaret Thompson, MD
Mary Noel, PhD, RD
Michigan State University
College of Human Medicine
East Lansing
1. Ferry HF, Grissino LM, Runfola PS. Tobacco dependence curricula in US un-
dergraduate medical education. JAMA. 1999;282:825-829.
2. Liaison Committee on Medical Education. Functions and Structure of a Medi-
cal School. Chicago, Ill: Council on Medical Education, American Medical Asso-
ciation; 1991:14.
3. US Department of Health and Human Services. Smoking Cessation, Clinical
Practice Guideline No. 18. Rockville, Md: US Dept of Health and Human Ser-
vices, Agency for Health Care Policy and Research; 1996. AHCPR publication 96-
0692.
4. Mavis BE, Henry RC, Ogle KS, Hoppe RB. The emperor’s new clothes: the OSCE
reassessed. Acad Med. 1996;71:447-453.
In Reply: While conducting our survey, we learned from fac-
ulty at several medical schools that clinical training and evalu-
ation of nicotine dependence is most commonly incorporated
in the primary care clerkships, as described by Dr Wadland and
colleagues. Objective structured clinical examinations (OSCEs)
are increasingly used in the third and fourth years to evaluate
mastery of interviewing, physical diagnosis, and counseling
skills. We know of a few medical schools that currently incor-
porate nicotine dependence treatment into their OSCE panel
of cases, similar to those at the Michigan State University Col-
lege of Human Medicine. Their encouraging outcome is con-
sistent with other studies that show that medical students can
develop skills in counseling nicotine-dependent patients.1,2 Un-
fortunately, schools with such commitments to nicotine de-
pendence education remain in the minority.
Since our 1997 survey, other schools may have improved their
nicotine dependence curricula. We are soliciting any teaching
material, (eg, curriculum goals and objectives, OSCE case de-
scriptions, videotapes, teaching manuals, handouts, interac-
tive computer training program, role playing, problem-based
learning, and evaluation tools) to create a syllabus of the best
examples for distribution to all medical school faculty, and would
be happy to receive any such material.
The release of the revised AHRQ clinical practice guide-
lines for smoking cessation in 2000 will be an opportunity for
medical schools to reevaluate their basic and clinical science
curriculum for the content areas suggested as requisite for all
physicians.3 If the clinical training skills recommended by the
AHRQ panel are followed, the next survey of medical school
curricula would ideally find no medical school reporting less
than 1 hour of nicotine dependence training in the clinical years.
In our survey, this minimal level was not met in 46.6% of the
third-year curricula and in 79.3% of fourth-year curricula.
The most costly and lethal health behavior in the United States
is still overlooked in most medical school curricula. The simple
inclusion of didactic presentations, without evidence that stu-
dents can demonstrate skills and application of the knowl-
edge, is not the answer. Curricula like those described by Wad-
land and colleagues demonstrate the effective training physicians
will need for nicotine dependence interventions in the 21st cen-
tury.
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CORRECTIONS
Omission: In the Preliminary Communication entitled “The Relationship Be-
tween Cyclooxygenase-2 Expression and Colorectal Cancer” in the October 6, 1999,
issue of THE JOURNAL (1999;282:1254-1257), Ms Theresa Keane was omitted from
the acknowledgment. The authors thank Ms Keane for her technical assistance.
Incorrect Color Reproduction: In the same Preliminary Communication, the col-
ors of the 4 photomicrographs in Figure 1 on page 1255 were incorrectly repro-
duced. The correct image is shown below.
Figure 1. Cells Stained for Cyclooxygenase-2 (COX-2)
A
C
B
D
A, COX-2 expression in colon cancer epithelial cells; B, COX-2 expression in tu-
mor vascular endothelium and stroma; C, inhibition of COX staining in colon can-
cer epithelial cells after preabsorption of anti–COX-2 antibody with COX-2 poly-
peptide; and D, normal colonic epithelium cells. COX-2 staining appears brown.
Following antibody incubation, color was developed by immersion of the sections
in diaminobenzidine tetrahydrochloride/hydrogen peroxide solution for 2 min-
utes. Sections were counterstained with hematoxylin (original magnification 340).
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